Cargando…
Therapeutic approaches for SARS-CoV-2 infection
Therapeutic approaches to COVID-19 treatment require appropriate inhibitors to target crucial proteins of SARS-CoV-2 replication machinery. It’s been approximately 12 months since the pandemic started, yet no known specific drugs are available. However, research progresses with time in terms of high...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096528/ https://www.ncbi.nlm.nih.gov/pubmed/33962011 http://dx.doi.org/10.1016/j.ymeth.2021.04.026 |
_version_ | 1783688178213847040 |
---|---|
author | Gupta, Ankur Pradhan, Anish Maurya, Vimal K. Kumar, Swatantra Theengh, Angila Puri, Bipin Saxena, Shailendra K. |
author_facet | Gupta, Ankur Pradhan, Anish Maurya, Vimal K. Kumar, Swatantra Theengh, Angila Puri, Bipin Saxena, Shailendra K. |
author_sort | Gupta, Ankur |
collection | PubMed |
description | Therapeutic approaches to COVID-19 treatment require appropriate inhibitors to target crucial proteins of SARS-CoV-2 replication machinery. It’s been approximately 12 months since the pandemic started, yet no known specific drugs are available. However, research progresses with time in terms of high throughput virtual screening (HTVS) and rational design of repurposed, novel synthetic and natural products discovery by understanding the viral life cycle, immuno-pathological and clinical outcomes in patients based on host’s nutritional, metabolic, and lifestyle status. Further, complementary and alternative medicine (CAM) approaches have also improved resiliency and immune responses. In this article, we summarize all the therapeutic antiviral strategies for COVID-19 drug discovery including computer aided virtual screening, repurposed drugs, immunomodulators, vaccines, plasma therapy, various adjunct therapies, and phage technology to unravel insightful mechanistic pathways of targeting SARS-CoV-2 and host’s intrinsic, innate immunity at multiple checkpoints that aid in the containment of the disease. |
format | Online Article Text |
id | pubmed-8096528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80965282021-05-05 Therapeutic approaches for SARS-CoV-2 infection Gupta, Ankur Pradhan, Anish Maurya, Vimal K. Kumar, Swatantra Theengh, Angila Puri, Bipin Saxena, Shailendra K. Methods Article Therapeutic approaches to COVID-19 treatment require appropriate inhibitors to target crucial proteins of SARS-CoV-2 replication machinery. It’s been approximately 12 months since the pandemic started, yet no known specific drugs are available. However, research progresses with time in terms of high throughput virtual screening (HTVS) and rational design of repurposed, novel synthetic and natural products discovery by understanding the viral life cycle, immuno-pathological and clinical outcomes in patients based on host’s nutritional, metabolic, and lifestyle status. Further, complementary and alternative medicine (CAM) approaches have also improved resiliency and immune responses. In this article, we summarize all the therapeutic antiviral strategies for COVID-19 drug discovery including computer aided virtual screening, repurposed drugs, immunomodulators, vaccines, plasma therapy, various adjunct therapies, and phage technology to unravel insightful mechanistic pathways of targeting SARS-CoV-2 and host’s intrinsic, innate immunity at multiple checkpoints that aid in the containment of the disease. Elsevier Inc. 2021-11 2021-05-05 /pmc/articles/PMC8096528/ /pubmed/33962011 http://dx.doi.org/10.1016/j.ymeth.2021.04.026 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Gupta, Ankur Pradhan, Anish Maurya, Vimal K. Kumar, Swatantra Theengh, Angila Puri, Bipin Saxena, Shailendra K. Therapeutic approaches for SARS-CoV-2 infection |
title | Therapeutic approaches for SARS-CoV-2 infection |
title_full | Therapeutic approaches for SARS-CoV-2 infection |
title_fullStr | Therapeutic approaches for SARS-CoV-2 infection |
title_full_unstemmed | Therapeutic approaches for SARS-CoV-2 infection |
title_short | Therapeutic approaches for SARS-CoV-2 infection |
title_sort | therapeutic approaches for sars-cov-2 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096528/ https://www.ncbi.nlm.nih.gov/pubmed/33962011 http://dx.doi.org/10.1016/j.ymeth.2021.04.026 |
work_keys_str_mv | AT guptaankur therapeuticapproachesforsarscov2infection AT pradhananish therapeuticapproachesforsarscov2infection AT mauryavimalk therapeuticapproachesforsarscov2infection AT kumarswatantra therapeuticapproachesforsarscov2infection AT theenghangila therapeuticapproachesforsarscov2infection AT puribipin therapeuticapproachesforsarscov2infection AT saxenashailendrak therapeuticapproachesforsarscov2infection |